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DOI:10.1097/HCO.0000000000000194The overall prevalence of hypertension is high and
likely to further increase with aging, obesity and
other risk factors. In fact, in the United States, the
International Statistical Classification of Diseases
and Related Health Problems code for hypertension
is by far the most common single code used by
practicing physicians. Although the benefits of anti-
hypertensive therapy have been established by a
solid bulk of evidence and rates of hypertension
awareness, treatment and control have been
improving over recent decades; they are still far from
adequate. Moreover, several misconceptions persist
among practicing clinicians, commonly in the
areas in which evidence is scarce, misinterpreted
or substituted by eminence.
For instance, hydrochlorothiazide remains by
far the most commonly prescribed antihypertensive
agent in the United States and worldwide. Yet, as
pointed out by DrWanpen Vongpatanasin (pp. 361–
365) in her provocative review, hydrochlorothiazide
in itsusualdoseof12.525mgperdayhasneverbeen
shown to reduce the risk of MI, stroke or death. Also,
meta-analysis of clinical trials showed that, for any
given difference in achieved clinic SBP, hydrochlor-
othiazide therapy was associated with 18% higher
adverse cardiovascular events when compared with
chlorthalidone. Clearly, therefore, chlorthalidone or
indapamide should be preferred over hydrochloro-
thiazide in hypertensive patients whenever diuretics
are required for the treatment of hypertension.
Dr Steven G. Chrysant (pp. 383-390) tackles
another common misconception, namely that anti-
hypertensive therapy causes erectile dysfunction (ED).
Indeed, erectile dysfunction is common in treated
hypertensive men. However, as Dr Chrysant suggests,
we have to ask whether the ED is due to hypertension
per se, the antihypertensive regimen or a combination
of both. Of note, data from randomized studies on ED
and antihypertensive therapy are limited; as of today,
the issue remains very much an evidence-free zone. It
should not be forgotten that knowledge by the patient
of the drug and its action on erectile dysfuction (ED)
may increase the incidence of ED (Hawthorn’s effect).
Dual reninangiotensin blockade was very
much in fashion in the early part of this century;ht © 2015 Wolters Kluwe
rs Kluwer Health, Inc. All rights reseprimarily accepted and promoted by nephrologists
but even increasingly popular among practicing
cardiologists. The concept seemed so logical and
appealing that benefits in surrogate end points,
such as blood pressure, proteinuria and endothelial
dysfunction, became accepted as a free pass for this
combination having cardioprotective and nephro-
protective effects. Drs Johannes F.E. Mann and
Michael Bo¨hm (pp. 373–377) clearly show that ‘it
ain’t necessarily so’ and discuss three randomized
controlled trials which ruled out benefits of dual
reninangiotensin blockade on major cardiovascu-
lar outcomes and reported substantial adverse
effects. Indeed, hyperkalemia, acute renal injury,
symptomatic hypotension and syncope were com-
mon with dual reninangiotensin blockade,
strongly arguing against such therapy.
Drs Carolina I. Valdiviezo, Lisa Martin and
Gurusher S. Panjrath (pp. 378–382) analyze the
important question of the target blood pressure
during antihypertensive therapy. They thoroughly
show that the dictum ‘the lower, the better’ which
was guidingmany of us for years is no longer accept-
able. Recent data support a target SBP of below
140mmHg among patients with hypertension or
cardiovascular disease, and achievement of this tar-
get may, in contrast to some recent guidelines,
benefit those older than 60 years of age as well.
However, treating to SBPs below 120mmHg may
not result in further benefit. Also, there may be
target organ heterogeneity in that the nadir of the
J-curve may differ from one cardiovascular outcome
to another, that is, the optimal blood pressure for
prevention of stroke may be lower than the one for
prevention of coronary artery disease.
Finally, we have been taught for decades, mostly
by nephrologists, that thiazide diuretics are ineffec-
tive antihypertensive agents in moderate-to-
advanced renal disease and that in this situation ar Health, Inc. All rights reserved.
rved. www.co-cardiology.com
Hypertensionswitch to loop diuretics was mandatory. Drs Arjun
D. Sinha and Rajiv Agarwal (pp. 366–372) analyze
the observational data and small randomized stud-
ies including their own suggesting the opposite,
namely, that thiazide diuretics can result in mean-
ingful blood pressure reduction in such patients.
These data reinforce the need for a randomized trial
to demonstrate safety and efficacy of thiazides in
advanced chronic kidney disease. The dictum that
thiazide diuretics are good antihypertensives but
poor diuretics and loop diuretics are poor antihy-
pertensives but good diuretics seems to hold true, at Copyright © 2015 Wolters Kluwer 
360 www.co-cardiology.comleast to some extent in moderate-to-advanced renal
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